Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02022306 · ClinicalTrials.gov registry record · Phase 1
TD-6450 SAD and MAD in Healthy Subjects
A Phase 1 study of Hepatitis C, sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 111
- Enrollment target
- 1
- Study location
NCT02022306 is a Phase 1 study of Hepatitis C that has completed, run by Theravance Biopharma. The registered enrollment target is 111 participants, below the 1,889-participant average among 106 other Hepatitis C trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02022306, a Phase 1 study of Hepatitis C, has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 111 participants
- Enrollment target
- 1
- Study location
Study Summary
This study consists of two parts, Parts A and B. Part A is a single ascending dose (SAD) study in healthy subjects. Part B is a multiple ascending dose (MAD) study in healthy subjects.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TD-6450
Study Locations (1)
Texas
- ICON Development Solutions - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02022306
The ClinicalTrials.gov registry entry for NCT02022306 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,889-participant average among 106 other Hepatitis C trials with a reported enrollment target (94% lower). The listed sponsor is Theravance Biopharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02022306 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02022306 about?
NCT02022306 is a clinical study titled "TD-6450 SAD and MAD in Healthy Subjects". This study consists of two parts, Parts A and B. Part A is a single ascending dose (SAD) study in healthy subjects. Part B is a multiple ascending dose (MAD) study in healthy subjects.
What is the current status of trial NCT02022306?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 111 participants. The study started on 2014-02. Estimated completion is 2014-09.
What conditions does trial NCT02022306 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT02022306?
The interventions under investigation include: Placebo (DRUG), TD-6450 (DRUG).
Who is sponsoring clinical trial NCT02022306?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02022306 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.
COMPLETED · Phase 1
-
Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection
COMPLETED · Phase 1
-
Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection
COMPLETED · Phase 1
-
Open-Label Hepatic Impairment Study
COMPLETED · Phase 1
-
Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805
COMPLETED · Phase 1
-
Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.